Analysts See $-0.31 EPS for Celsion Corporation (CLSN)

February 15, 2018 - By Adrian Mccoy

 Analysts See $ 0.31 EPS for Celsion Corporation (CLSN)

Analysts expect Celsion Corporation (NASDAQ:CLSN) to report $-0.31 EPS on March, 15.They anticipate $1.65 EPS change or 84.18 % from last quarter’s $-1.96 EPS. After having $-0.39 EPS previously, Celsion Corporation’s analysts see -20.51 % EPS growth. The stock increased 2.74% or $0.06 during the last trading session, reaching $2.25. About 146,207 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 82.71% since February 15, 2017 and is downtrending. It has underperformed by 99.41% the S&P500.

Celsion Corporation (NASDAQ:CLSN) Ratings Coverage

Among 2 analysts covering Celsion (NASDAQ:CLSN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celsion had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Hold” on Tuesday, August 15. The stock of Celsion Corporation (NASDAQ:CLSN) earned “Buy” rating by Cantor Fitzgerald on Friday, August 7. The rating was upgraded by Zacks to “Hold” on Wednesday, August 12. The company was maintained on Monday, August 7 by Maxim Group. Maxim Group maintained Celsion Corporation (NASDAQ:CLSN) rating on Tuesday, January 19. Maxim Group has “Buy” rating and $9.0 target. The firm has “Hold” rating given on Thursday, November 10 by Maxim Group. Oppenheimer initiated it with “Buy” rating and $9.0 target in Monday, November 20 report. As per Thursday, June 1, the company rating was maintained by Maxim Group. The firm has “Buy” rating given on Thursday, October 5 by Maxim Group.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $36.14 million. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

More important recent Celsion Corporation (NASDAQ:CLSN) news were published by: which released: “Celsion Turns Up The Heat On Cancer” on November 23, 2017, also published article titled: “Celsion Corporation Provides Corporate Update and 2018 Outlook”, published: “Celsion Announces ThermoDox┬« HEAT Study Presentation at Korean Liver Cancer …” on February 12, 2018. More interesting news about Celsion Corporation (NASDAQ:CLSN) was released by: and their article: “Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides …” with publication date: November 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.